Sobi to present clinical data on Gamifant at Histiocyte Society meeting

Swedish biopharmaceutical company Sobi announced that new clinical data concerning its drug Gamifant® (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026). The conference is scheduled to take place from September 26-29 in Rotterdam, the Netherlands.

The presented abstracts include a pooled analysis of pre- and post-transplant survival outcomes across three prospective trials. Additionally, two encore presentations of prior analyses in primary HLH will be shown, alongside data from a post-authorization study involving treatment-experienced Chinese patients.

"Sobi is continuing to build the evidence on treatment and transplant outcomes in primary HLH to help people with this rare, life-threatening hyperinflammatory disease," said Lydia Abad-Franch, Sobi's Head of R&D and Medical Affairs and Chief Medical Officer. "The new pooled-analysis has been selected as one of the ten highest-scoring poster abstracts and nominated for the Robert J. Arceci Prize for Best Poster, which is highly encouraging as it recognises our scientific impact."

Gamifant is identified as the only approved anti-interferon gamma (IFNγ) monoclonal antibody. It functions by binding to and neutralizing IFNγ, a cytokine implicated in the uncontrolled hyperinflammation characteristic of HLH. In the United States, Gamifant is approved for adult and pediatric patients with primary HLH who have refractory, recurrent, or progressive disease, or intolerance to conventional therapies. It is also approved for HLH/macrophage activation syndrome (MAS) in adult and pediatric patients with known or suspected Still's disease who have had an inadequate response or intolerance to glucocorticoids.